Gainplan LLC Invests $388,000 in Nektar Therapeutics $NKTR

Gainplan LLC bought a new position in Nektar Therapeutics (NASDAQ:NKTR) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 15,000 shares of the biopharmaceutical company’s stock, valued at approximately $388,000.

Several other hedge funds also recently added to or reduced their stakes in NKTR. Acadian Asset Management LLC grew its holdings in Nektar Therapeutics by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 7,301,734 shares of the biopharmaceutical company’s stock valued at $4,961,000 after purchasing an additional 100,645 shares during the last quarter. Almitas Capital LLC grew its holdings in Nektar Therapeutics by 401.1% during the 1st quarter. Almitas Capital LLC now owns 4,610,872 shares of the biopharmaceutical company’s stock valued at $3,135,000 after purchasing an additional 3,690,647 shares during the last quarter. AQR Capital Management LLC grew its holdings in Nektar Therapeutics by 336.9% during the 1st quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after purchasing an additional 2,807,595 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Nektar Therapeutics by 14.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 3,007,928 shares of the biopharmaceutical company’s stock valued at $2,045,000 after purchasing an additional 380,967 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in Nektar Therapeutics by 253.1% during the 1st quarter. Mackenzie Financial Corp now owns 1,658,745 shares of the biopharmaceutical company’s stock valued at $1,128,000 after purchasing an additional 1,188,976 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors.

Insider Activity at Nektar Therapeutics

In other news, insider Jonathan Zalevsky sold 1,721 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $33.52, for a total value of $57,687.92. Following the completion of the sale, the insider owned 17,462 shares of the company’s stock, valued at approximately $585,326.24. This represents a 8.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Howard W. Robin sold 6,666 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $46.69, for a total transaction of $311,235.54. Following the completion of the sale, the chief executive officer directly owned 49,342 shares of the company’s stock, valued at $2,303,777.98. The trade was a 11.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,178 shares of company stock valued at $938,776 in the last ninety days. Corporate insiders own 3.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. BTIG Research reiterated a “buy” rating and set a $100.00 price target on shares of Nektar Therapeutics in a report on Friday, September 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Saturday, September 27th. B. Riley upped their price target on shares of Nektar Therapeutics from $85.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, September 23rd. Finally, HC Wainwright upped their price target on shares of Nektar Therapeutics to $120.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.67.

Nektar Therapeutics Price Performance

Shares of NKTR stock opened at $58.00 on Wednesday. The company has a market capitalization of $1.10 billion, a P/E ratio of -6.59 and a beta of 1.18. The company’s 50-day simple moving average is $39.14 and its two-hundred day simple moving average is $22.78. Nektar Therapeutics has a one year low of $6.45 and a one year high of $62.95.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) EPS for the quarter, topping analysts’ consensus estimates of ($3.13) by $0.18. The business had revenue of $11.18 million for the quarter, compared to the consensus estimate of $9.42 million. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%. On average, research analysts expect that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.